Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?

The improvement in cancer therapy and the increasing number of long term survivors unearth the issue of cardiovascular side effects of anticancer treatments. As a paradox in cancer survivors, delayed cardiotoxicity has emerged as a significant problem. Two categories of cardiotoxic side effects of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Riccio, Gennaro, Coppola, Carmela, Piscopo, Giovanna, Capasso, Immacolata, Maurea, Carlo, Esposito, Emanuela, De Lorenzo, Claudia, Maurea, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963071/
https://www.ncbi.nlm.nih.gov/pubmed/26836985
http://dx.doi.org/10.1080/21645515.2015.1125056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963071/
https://www.ncbi.nlm.nih.gov/pubmed/26836985
http://dx.doi.org/10.1080/21645515.2015.1125056

Ejemplares similares